RNA Interference against Platelet-Derived Growth Factor Receptor α mRNA Inhibits Fibroblast Transdifferentiation in Skin Lesions of Patients with Systemic Sclerosis

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

(2011) R. F. Spiera et al.   ANNALS OF THE RHEUMATIC DISEASES

Angiogenic cytokines and growth factors in systemic sclerosis

(2011) Vasiliki Liakouli et al.   AUTOIMMUNITY REVIEWS

Blockade of PDGF receptor signaling reduces myofibroblast number and attenuates renal fibrosis

(2011) Valerie S. LeBleu et al.   KIDNEY INTERNATIONAL

Possible strategies for anti-fibrotic drug intervention in scleroderma

(2011) Andrew Leask   Journal of Cell Communication and Signaling

Future treatments in systemic sclerosis

(2010) Yoshihide ASANO   JOURNAL OF DERMATOLOGY

RNA interference targeting the platelet-derived growth factor receptor β subunit ameliorates experimental hepatic fibrosis in rats

(2010) Si-Wen Chen et al.   LIVER INTERNATIONAL

Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations

(2010) Jessica Gordon et al.   Current Rheumatology Reports

The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis

(2009) Nicole Reich et al.   ARTHRITIS AND RHEUMATISM

Systemic Sclerosis at the Cellular Level: Molecular Pathways of Pathogenesis and its Implication on Future Drug Design

(2009) S. Schulz et al.   CURRENT MEDICINAL CHEMISTRY

RNA interference as a gene knockdown technique

(2009) Ge Shan   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Role of PDGF in fibrotic diseases and systemic sclerosis

(2008) M. Trojanowska   RHEUMATOLOGY

Imatinib for the treatment of refractory, diffuse systemic sclerosis

(2008) P. P. Sfikakis et al.   RHEUMATOLOGY

Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis

(2007) Hironobu Ihn   JOURNAL OF DERMATOLOGICAL SCIENCE